Alzheimer’s disease affects so many; the numbers are staggering. As shocking as they are, they’re more than just statistics to those of us who have personally experienced, in some way, the loss the disease brings. Today 5.8 million Americans are battling an Alzheimer’s diagnosis, and this number will increase greatly as the population ages. What’s more shocking is that nearly 100% of experimental Alzheimer's drug treatments have failed to show clinical benefits.
A disease with such a great impact continues, of course, to draw the attention of pharmaceutical companies. There have been more than 100 drugs that have made it as far as clinical trials and researchers and investors have recently been keeping a close eye on three new drugs: solanezumab (Eli Lilly), gantenerumab (Roche), and aducanumab (Biogen).